Recombinant Human Neuropilin-2 Fc Chimera Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 2215-N2
Key Product Details
Source
Accession #
Structure / Form
Conjugate
Applications
Product Specifications
Source
Human Neuropilin-2 (Gln23-Tyr855) Accession #Q7LBX6 |
IEGRMD | Human IgG1 (Pro100-Lys330) |
N-terminus | C-terminus |
Purity
Endotoxin Level
N-terminal Sequence Analysis
Predicted Molecular Mass
SDS-PAGE
Activity
Immobilized Recombinant Human (rh) Neuropilin‑2 Fc Chimera can bind rhVEGF165 with an apparent KD < 5 nM.
Reviewed Applications
Read 1 review rated 3 using 2215-N2 in the following applications:
Formulation, Preparation and Storage
2215-N2
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution |
Reconstitute at 100 μg/mL in sterile PBS.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: Neuropilin-2
Neuropilin-2 (Npn-2) is a 120 kDa, type I transmembrane (TM) glycoprotein that is related to the semaphorin receptor now known as Neuropilin-1 (1). Npn-2 is a complex molecule with multiple splice forms. Five transmembrane forms are known, and one 62 kDa soluble form has been identified (2). Based on the originally reported precursor size of 909 amino acids (aa), the “standard” precursor in human will have a 20 aa signal sequence, an 842 aa extracellular region, a 25 aa TM segment, and a 42 aa cytoplasmic tail (1). The extracellular region contains two N-terminal CUB (C1r/Ugef/BMP-1) domains, two jellyroll-shaped coagulation factor V type C domains, and a juxtamembrane MAM (meprin/A-5 protein/tyrosine phosphatase μ) domain (1, 3). The CUB and factor V domain are involved in VEGF and semaphorin binding. The MAM domain appears necessary for signaling through plexin-1 (4). The five transmembrane isoforms all share the same CUB, factor V and MAM domains. Splicing begins at aa 809, seven amino acids after the end of the MAM domain, and it involves the end of the extracellular region, the TM segment, and the cytoplasmic domain (a total of 101 aa). Two of the four variants show a complete replacement of these 101 aa with a totally unrelated stretch of approximately 90 aa. This creates a new TM and cytoplasmic tail. These forms are called “Npn-2b” forms. Two other isoforms (plus the standard 909 aa form) retain the 101 aa stretch, and add either 17 or 22 aa to the end of the extracellular region. These forms are called “Npn-2a” forms. The isoform offered by R&D Systems is the “a” form with the 17 aa addition. This isoform shows 94% aa identity to the equivalent regions in mouse and rat Npn-2. The soluble form of Npn-2 is 555 aa in precursor length, and contains the two CUB domains plus the first 1½ factor V type C domains (1). Npn-2 binds Sema3B through F, and VEGF isoforms 165, 145, PlGF-2 and VEGF-C (5). It is known to form homodimers and heterodimers with Npn-1, and it forms receptor complexes with plexin-1 and VEGF R1 (4, 5). Npn-2 is found on a variety of cell types including neurons (motor, autonomic, sensory), vascular endothelial cells, Schwann cells and pancreatic acinar cells.
References
- Chen, H. et al. (1997) Neuron 19:547.
- Rossignol, M. et al. (2000) Genomics 70:211.
- He, Z. and M. Tessier-lavigne (1997) Cell 90:739.
- Nakamura, F. and Y. Goshima (2002) Adv. Exp. Med. Biol. 515:55.
- Neufeld, G. et al. (2002) Adv. Exp. Med. Biol. 515:81.
Alternate Names
Gene Symbol
UniProt
Additional Neuropilin-2 Products
Product Documents for Recombinant Human Neuropilin-2 Fc Chimera Protein, CF
Product Specific Notices for Recombinant Human Neuropilin-2 Fc Chimera Protein, CF
This product or the use of
this product is covered by U.S. Patents owned by The Regents of the University of California. This product is for research
use only and is not to be used for commercial purposes. Use of this product to
produce products for sale or for diagnostic, therapeutic or drug discovery
purposes is prohibited. In order to obtain a license to use this product for
such purposes, contact The Regents of the University of California.
U.S. Patent # 6,054,293, 6,623,738, and
other U.S.
and international patents pending.
For research use only